Poultice

The poultice formulation with ketoprofen, propylene glycol, and l-menthol stabilizes ketoprofen, addressing storage instability and maintaining therapeutic efficacy for prolonged periods.

JP7595635B2Active Publication Date: 2024-12-06HISAMITSU PHARM CO INC
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2022211679
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-02-14
Filing Date
2022-12-28
Publication Date
2024-12-06
Estimated Expiration
2040-02-13

Smart Images

  • Figure 0007595635000001
    Figure 0007595635000001
  • Figure 0007595635000002
    Figure 0007595635000002
  • Figure 0007595635000003
    Figure 0007595635000003
Patent Text Reader

Abstract

To provide a poultice having excellent storage stability of ketoprofen. [Solution] A cataplasm comprising a paste layer on a support, the paste layer containing ketoprofen or a pharmaceutically acceptable salt thereof, propylene glycol, l-menthol, water, and at least one of poly(methyl acrylate / 2-ethylhexyl acrylate) and poly(methacrylic acid / n-butyl acrylate), wherein the mass of propylene glycol in the paste layer is no more than three times the mass of ketoprofen, and the l-menthol content is 0.1 to 0.5 mass% based on the total mass of the paste layer.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a poultice and a method for producing the same. [Background technology]

[0002] A cataplasm is a type of patch produced by spreading a drug-containing paste layer on a support such as cloth, and generally contains a lot of water, has a thick paste layer, and is characterized by low skin irritation. In addition, the adhesive strength of a cataplasm often decreases over time after application, and development of a cataplasm that does not lose adhesive strength even when applied for a long period of time is being considered (Patent Documents 1 to 4).

[0003] Patent Document 1 discloses that the decrease in adhesive strength can be suppressed by blending poly(methyl acrylate / 2-ethylhexyl acrylate) into a cataplasm containing a partially neutralized polyacrylic acid. In particular, Patent Document 2 discloses that the blending of polyacrylic acid in the plaster layer results in a cataplasm with excellent moldability and shape retention. In addition, since the cataplasm contains a drug in the hydrous plaster layer, the skin permeability of the drug tends to be lower than that of a tape (e.g., Patent Document 3). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2006 / 090782 [Patent Document 2] International Publication No. 2015 / 025935 [Patent Document 3] International Publication No. 2015 / 129808 [Patent Document 4] Japanese Patent Application Publication No. 10-95728 Summary of the Invention [Problem to be solved by the invention]

[0005] The present inventors, while investigating the development of a cataplasm containing ketoprofen as an active ingredient, found that a portion of ketoprofen is likely to be converted to its ester analogue by transesterification during storage of the cataplasm. Therefore, an object of the present invention is to provide a cataplasm having excellent storage stability of ketoprofen. [Means for solving the problem]

[0006] [1] A poultice comprising a paste layer on a support, the paste layer containing ketoprofen or a pharma- ceutically acceptable salt thereof, propylene glycol, l-menthol, and water, the mass of propylene glycol in the paste layer being 3 times or less the mass of ketoprofen, and the l-menthol content being 0.1 to 0.5 mass% based on the total mass of the paste layer. [2] The poultice according to [1], wherein the paste layer further contains a fatty acid alkyl ester. [3] A method for stabilizing ketoprofen in a poultice having a plaster layer containing ketoprofen or a pharma- ceutically acceptable salt thereof on a support, comprising adding propylene glycol to the plaster layer in an amount three times or less by mass of ketoprofen. Effect of the Invention

[0007] According to the present invention, a cataplasm having excellent storage stability of ketoprofen can be provided. By improving the storage stability of ketoprofen, the expiration date of the cataplasm as a medicine can be extended, which is beneficial from the viewpoints of stable supply of medicine, reduction of economic burden on users, reduction of environmental burden, etc.

[0008] In this specification, "excellent storage stability of ketoprofen" means that the amount of ketoprofen ester produced is small, and for example, when the content of ketoprofen ester analogues in the paste layer after storage at 60°C for 2 weeks is 2.1% or less, preferably 1.9% or less based on the content of ketoprofen immediately after preparation of the poultice, the storage stability of ketoprofen can be judged to be excellent. When the content of ketoprofen ester analogues is 2.1% or less, the therapeutic effect of ketoprofen as a pharmaceutical product can be exhibited sufficiently even after 2 years have passed since production. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Preferred embodiments of the present invention will now be described in detail.

[0010] A poultice according to one embodiment of the present invention is a poultice comprising a paste layer on a support, the paste layer containing ketoprofen or a pharma- ceutically acceptable salt thereof, propylene glycol, l-menthol, and water, the mass of propylene glycol in the paste layer being 3 times or less the mass of ketoprofen, and the content of l-menthol being 0.1 to 0.5 mass% based on the total mass of the paste layer.

[0011] The support may be any one that can support the water-containing paste, and may be any one known to those skilled in the art. Examples of the support include woven fabric (including knitted fabric), nonwoven fabric, resin film, foam sheet, and paper. When using woven fabric, nonwoven fabric, or resin film as the support, the material may include, for example, polyolefins such as polyethylene, polypropylene, and polybutylene, polyesters such as polyethylene terephthalate, rayon, polyurethane, and cotton, and these may be used alone or in combination of two or more. Polyester is more preferable as the material of the support.

[0012] The support is preferably a nonwoven fabric or a woven fabric, and particularly preferably a nonwoven fabric or a woven fabric having a predetermined elongation recovery rate (elongation elasticity). In this specification, "elongation recovery rate" is a value measured according to the description in JIS L1096:2010, and means "elongation elasticity at constant load" or "elongation elasticity at constant rate elongation". For example, "50% elongation recovery rate" is the elongation elasticity when elongated to an elongation rate of 50% (constant rate elongation), and "load at 50% elongation" is the load (constant load) required to elongate to an elongation rate of 50%. By using a nonwoven fabric or a woven fabric having a predetermined elongation recovery rate, the support expands and contracts according to the movement of the application site when applied to a movable part such as a joint, and is therefore preferable.

[0013] When the support is a nonwoven fabric, for example, the recovery rate of the nonwoven fabric at 50% elongation is 60 to 99%, preferably 65 to 95%, and more preferably 70 to 90%. The load of the nonwoven fabric at 50% elongation is, for example, 1 to 5 N / 2.5 cm in the longitudinal direction (long axis direction) and 0.1 to 3 N / 2.5 cm in the transverse direction (short axis direction). The basis weight of the suitable support is, for example, 80 to 120 g / m 2 90-110g / m 2 It is preferable that the thickness of the support is, for example, 0.5 to 2 mm. The bending resistance of the support (the bending resistance is measured by JIS L1096:2010, Method A (45° cantilever method)) can be, for example, 20 to 40 mm in the longitudinal direction (long axis direction) and 10 to 35 mm in the transverse direction (short axis direction), and is preferably 25 to 35 mm in the longitudinal direction (long axis direction) and 15 to 30 mm in the transverse direction (short axis direction). It is preferable that the thickness of the nonwoven fabric is 0.5 to 2 mm. The basis weight of the nonwoven fabric is 80 to 150 g / m 2 It is preferable that:

[0014] The knitted fabric used as the support also includes knitted fabrics processed into a cloth by assembling stitches by circular knitting, warp knitting, weft knitting, etc. Knitted fabrics made of one or a combination of two or more materials such as polyester, nylon, polypropylene, rayon, etc. are preferred, and among them, knitted fabrics made of polyethylene terephthalate, which has little interaction with drugs, are more preferred.

[0015] In particular, when the support is a woven fabric, the 50% elongation recovery rate of the woven fabric is, for example, 60 to 99%, preferably 65 to 95%, and more preferably 70 to 90%. The load at 50% elongation is, for example, 1 to 5 N / 2.5 cm in the longitudinal direction (long axis direction) and 0.1 to 3 N / 2.5 cm in the transverse direction (short axis direction). The bending resistance of the support can be, for example, 10 to 30 mm in the longitudinal direction (long axis direction) and 10 to 30 mm in the transverse direction (short axis direction), and is preferably 15 to 25 mm in the longitudinal direction (long axis direction) and 15 to 25 mm in the transverse direction (short axis direction). The thickness of the woven fabric is preferably 0.5 to 2 mm.

[0016] In particular, the basis weight is 80 to 150 g / m 2 When the polyethylene terephthalate woven fabric is used, the water contained in the paste is less likely to seep out through the meshes of the woven fabric during spreading, and the anchoring property between the woven fabric and the paste is more excellent.

[0017] In addition, the polyethylene terephthalate woven fabric preferably has a longitudinal (longitudinal) modulus of 2 to 12 N / 5 cm and a transverse (short-axis) modulus of 2 to 8 N / 5 cm (the modulus is measured according to JIS L1018:1999). If the modulus is lower than 2 N / 5 cm, the woven fabric may stretch when the paste is spread, causing the adhesive to soak into the mesh, resulting in a decrease in functionality as a poultice. If the modulus is higher than 12 N / 5 cm (longitudinal) or 8 N / 5 cm (transverse), the elasticity is poor and it may be difficult to follow the expansion of the skin when applied to a moving part.

[0018] The paste layer contains ketoprofen or a pharma- ceutically acceptable salt thereof, propylene glycol, and water.

[0019] Ketoprofen is a compound represented by the chemical formula (1) and exists as two optical isomers, R- and S-. In the present embodiment, ketoprofen of any one of the optical isomers may be used, or the two optical isomers may be mixed in any ratio. [ka]

[0020] Pharmaceutically acceptable salts of ketoprofen include inorganic salts such as sodium salts, potassium salts, calcium salts, etc.; amine salts such as monoethanolamine salts, diethanolamine salts, etc.

[0021] The content of ketoprofen in the paste layer is 1.5 to 2.5% by mass, and preferably 1.8 to 2.2% by mass, based on the mass of the entire paste layer. When the paste layer contains a pharma- ceutically acceptable salt of ketoprofen, the mass of the salt is converted into the mass of ketoprofen.

[0022] Propylene glycol is particularly effective in improving the skin permeability of ketoprofen. The content of propylene glycol in the paste layer is 3 times or less, and may be 0.5 to 3 times, 0.7 to 3 times, 1 to 3 times, 0.5 to 2.5 times, 0.7 to 2.5 times, 1 to 2.5 times, or 1.5 to 2.5 times the content of ketoprofen by mass.

[0023] The content of propylene glycol in the paste layer may be 1.5 to 6.5 mass %, 2.5 to 6.5 mass %, or 3 to 6 mass % based on the total mass of the paste layer.

[0024] The fatty acid alkyl ester may be an ester synthesized from a fatty acid and an alkyl alcohol. The alkyl alcohol may be, for example, an alkyl alcohol having 1 to 10 carbon atoms. In this specification, the fatty acid means a saturated or unsaturated alkyl carboxylic acid having 8 to 18 carbon atoms. Examples of the fatty acid alkyl ester include caprylic acid alkyl ester, capric acid alkyl ester, lauric acid alkyl ester, myristate alkyl ester, palmitic acid alkyl ester, palmitoleic acid alkyl ester, stearate alkyl ester, and oleic acid alkyl ester. A preferred fatty acid alkyl ester is hexyl laurate or isopropyl myristate. The fatty acid alkyl ester may be used alone or in combination of two or more. By containing a fatty acid alkyl ester, the skin permeability of ketoprofen can be improved.

[0025] The content of fatty acid alkyl ester in the paste layer may be 1-20% by mass, preferably 1-15% by mass or 2-13% by mass, based on the total mass of the paste layer. In particular, the content of hexyl laurate or isopropyl myristate may be 0.5-15% by mass or 0.5-10% by mass, preferably 0.5-5.0% by mass or 1.0-3.5% by mass, based on the total mass of the paste layer. When the content of hexyl laurate or isopropyl myristate is 0.5-5.0% by mass, the skin permeability of ketoprofen is particularly excellent.

[0026] The water content in the paste layer may be 30 to 60% by mass, or 35 to 50% by mass, based on the total mass of the paste layer.

[0027] The paste layer may further contain a neutralized polyacrylic acid. The neutralized polyacrylic acid may be a completely neutralized polyacrylic acid, a partially neutralized polyacrylic acid, or a mixture thereof. The neutralized polyacrylic acid may be a polyacrylic acid salt, such as a sodium salt, a potassium salt, a calcium salt, or an ammonium salt.

[0028] As the neutralized polyacrylic acid, a partially neutralized polyacrylic acid is preferred because it has high initial adhesion and adhesion over time. The partially neutralized polyacrylic acid is one in which structural units derived from acrylic acid and structural units derived from acrylic acid salts are present in any ratio in one polymer chain. As the partially neutralized polyacrylic acid, one in which 50 mol % of the carboxyl groups in one polymer chain are neutralized is preferably used.

[0029] The content of the neutralized polyacrylic acid in the paste layer is preferably 1 to 6% by mass, more preferably 2 to 6% by mass, based on the total mass of the paste layer. When the content of the neutralized polyacrylic acid is 1% by mass or more, the adhesive strength of the paste layer is sufficiently high and the paste layer is less likely to fall off. When the content of the neutralized polyacrylic acid is 6% by mass or less, the moldability and shape retention of the paste layer are improved.

[0030] The paste layer may further contain polyacrylic acid. By containing polyacrylic acid, the adhesive force retention performance is maintained high and the shape retention of the cataplasm is improved. The content of polyacrylic acid is preferably 1 to 5 mass% based on the mass of the paste layer. When the content of polyacrylic acid is 1 mass% or more, the moldability and shape retention of the paste layer are improved. When the content of polyacrylic acid is 5 mass% or less, the hardness of the paste layer is unlikely to increase, and the adhesion to the skin is increased. By containing both a neutralized polyacrylic acid and polyacrylic acid, the adhesiveness, moldability, shape retention, and hardness of the cataplasm are improved in a well-balanced manner.

[0031] The paste layer may further contain poly(methyl acrylate / 2-ethylhexyl acrylate) or poly(methacrylic acid / n-butyl acrylate). Poly(methyl acrylate / 2-ethylhexyl acrylate) is a copolymer of methyl acrylate and 2-ethylhexyl acrylate. Poly(methacrylic acid / n-butyl acrylate) is a copolymer of methacrylic acid and n-butyl acrylate. The content ratio of each monomer is not particularly limited.

[0032] Poly(methyl acrylate / 2-ethylhexyl acrylate) or poly(methacrylic acid / n-butyl acrylate) may be in the form of an emulsion (aqueous emulsion) dispersed in any solvent such as water or a water-containing organic solvent. An example of an aqueous emulsion of poly(methyl acrylate / 2-ethylhexyl acrylate) is Nicasol TS-620 (trade name, manufactured by Nippon Carbide Industries Co., Ltd.). An example of an aqueous emulsion of poly(methacrylic acid / n-butyl acrylate) is Primal N-580NF (trade name, manufactured by Rohm and Haas Co., Ltd.) and Ultrasol W-50 (trade name, manufactured by Aica Kogyo Co., Ltd.). When preparing a plaster fluid for a cataplasm, these copolymers are mixed with other components in the form of an aqueous emulsion, which makes it easier for these polymers to disperse throughout the plaster fluid. By dispersing these copolymers throughout the plaster layer, a more significant effect of suppressing the decrease in adhesive strength can be obtained, and sufficient adhesive strength can be exhibited even after a longer application.

[0033] The content of poly(methyl acrylate / 2-ethylhexyl acrylate) or poly(methacrylic acid / n-butyl acrylate) may be 2.75 to 15.75 mass% in terms of solids based on the total mass of the paste layer, and is preferably 3.3 to 13.86 mass%, 5.5 to 12.6 mass%, or 5.5 to 11.34 mass%.

[0034] The content of the aqueous emulsion of poly(methyl acrylate / 2-ethylhexyl acrylate) or poly(methacrylic acid / n-butyl acrylate) may be 5-25% by mass (2.75-15.75% by mass as solid content) based on the total mass of the paste layer, and is preferably 6-22% by mass (3.3-13.86% by mass as solid content), 10-20% by mass (5.5-12.6% by mass as solid content), or 10-18% by mass (5.5-11.34% by mass as solid content). For example, in Nicasol TS-620, the aqueous emulsion contains 55-63% poly(methyl acrylate / 2-ethylhexyl acrylate) as solid content. When the aqueous emulsion of the above polymer is used to produce a poultice, the water content in the paste layer described above also includes the amount of water added as a medium for the aqueous emulsion.

[0035] The paste layer may contain other ingredients such as other drugs, plant-derived ingredients, animal-derived ingredients, water-soluble polymers, solubilizing agents, crosslinking agents, moisturizing agents, cooling agents, stabilizers, inorganic powders, colorants, flavoring agents, and pH adjusters.

[0036] The other drug may be any physiologically active substance other than ketoprofen, as long as it has transdermal absorbability. Examples of other drugs include non-steroidal anti-inflammatory drugs such as felbinac, flurbiprofen, diclofenac, diclofenac sodium, methyl salicylate, glycol salicylate, indomethacin, and ketoprofen, or esters thereof, antihistamines such as diphenhydramine, analgesics such as aspirin, acetaminophen, ibuprofen, and loxoprofen sodium, local anesthetics such as lidocaine, muscle relaxants such as suxamethonium chloride, antifungal agents such as clotrimazole, antihypertensive agents such as clonidine, vasodilators such as nitroglycerin and isosorbide dinitrate, vitamins such as vitamin A, vitamin E (tocopherol), tocopherol acetate, vitamin K, octothiacin, and riboflavin butyrate, prostaglandins, scopolamine, fentanyl, l-menthol, capsicum extract, and vanillylamide nonylate.

[0037] The plant-derived component may be a component extracted from at least a part of a plant (e.g., leaves, roots, skin, fruit) or a hydrolysate thereof, and examples thereof include fruit-derived components such as apple extract, orange extract, orange juice, raspberry extract, kiwi extract, cucumber extract, gardenia extract, grapefruit extract, crawthorn extract, Japanese pepper extract, hawthorn extract, juniper extract, oak extract, duke extract, tomato extract, grape extract, loofah extract, lime juice, apple extract, apple juice, lemon extract, and lemon juice, allantoin, lecithin, amino acids, kojic acid, and components extracted from various herbal medicines such as aloe and licorice.In addition, the plant-derived ingredients are Angelica extract, Avocado extract, Hydrangea extract, Arnica extract, Ginkgo extract, Fennel extract, Turmeric extract, Oolong tea extract, Scutellaria extract, Phellodendron bark extract, Barley extract, Dutch mustard extract, Seaweed extract, Hydrolyzed elastin, Hydrolyzed wheat powder, Chamomilla extract, Artemisia capillaris extract, Licorice extract, Karkade extract, Guanosine, Sasa kumazasa extract, Walnut extract, Clematis extract, Burdock extract, Comfrey extract, Cowberry extract, Bupleurum extract, Salvia extract, Soapwort extract, Bamboo grass extract, Crataegus crenata extract, Shiitake mushroom extract, Rehmannia extract, Lithospermum root extract, Tilia extract, Spiraea japonica extract, Calamus root extract, Birch extract, Horsetail extract, Honeysuckle extract, Ivy extract, Crataegus monogyna extract, Elderberry extract extract, yarrow extract, peppermint extract, mallow extract, swertia japonica extract, tsargassum extract, thyme extract, clove extract, Imperata cylindrica extract, chinpi extract, spruce extract, dokudami extract, natto extract, carrot extract, wild rose extract, hibiscus extract, bamboo root extract, parsley extract, parietaria extract, sedge extract, bisabolol, coltsfoot extract, butterbur bud extract, podiatrist extract, butcher's broom extract, propolis, peppermint extract, linden extract, hop extract, pine extract, horse chestnut extract, skunk cabbage extract, soapberry extract, peach leaf extract, cornflower extract, eucalyptus extract, yuzu extract, mugwort extract, lavender extract, lettuce extract, astragalus extract, rose extract, rosemary extract, Roman chamomile extract, and the like.

[0038] The animal-derived component may be a component extracted from at least a part of an animal (e.g., placenta, umbilical cord) or a hydrolysate thereof, or a component produced by an animal, and examples thereof include placenta extract, umbilical cord extract, water-soluble placenta extract, hydrolyzed silk, honey, royal jelly extract, and yeast extract.

[0039] The water-soluble polymer is not particularly limited as long as it can retain moisture in the poultice, and those generally known to those skilled in the art can be used. Examples of the water-soluble polymer include gelatin, polyvinyl alcohol, polyvinylpyrrolidone, sodium alginate, hydroxypropyl cellulose, sodium carboxymethylcellulose (carmellose sodium), methylcellulose, and carrageenan. One type may be used alone, or two or more types may be used in combination. The water-soluble polymer is preferably carmellose sodium, gelatin, or polyvinyl alcohol. The content of the water-soluble polymer is preferably 3 to 20% by mass, or 3 to 10% by mass, based on the mass of the paste layer.

[0040] The solubilizing agent is not particularly limited as long as it can dissolve the drug, and examples thereof include surfactants such as crotamiton, N-methylpyrrolidone, polyalkylene glycols such as polyethylene glycol (PEG) and polybutylene glycol, oxyalkylene fatty acid esters such as polyethylene glycol monostearate, polyoxyalkylene sorbitan fatty acid esters such as polysorbate 80, and polyoxyethylene hydrogenated castor oil. These solubilizing agents may be used alone or in combination of two or more. The content of the solubilizing agent is preferably 0.1 to 10% by mass based on the mass of the paste layer.

[0041] The crosslinking agent is a component for adjusting the progress of the crosslinking reaction between the neutralized polyacrylic acid and the crosslinking reaction between the neutralized polyacrylic acid and the polyacrylic acid added optionally, and may be one generally used in the industry. Examples of the crosslinking agent include aluminum compounds. The content of the crosslinking agent is preferably 0.01 to 6% by mass based on the mass of the paste layer. When the content of the crosslinking agent is within this range, a poultice with better skin conformability can be obtained.

[0042] The moisturizing agent is not particularly limited as long as it can suppress the evaporation of water from the paste layer over time. Examples of the moisturizing agent include polyhydric alcohols such as concentrated glycerin, sorbitol, ethylene glycol, 1,4-butanediol, polyethylene glycol, and liquid paraffin. These moisturizing agents may be used alone or in combination of two or more. Concentrated glycerin is preferred as the moisturizing agent. The content of the moisturizing agent is preferably 20 to 40% by mass based on the mass of the paste layer.

[0043] Examples of the cooling agent include thymol, l-menthol, dl-menthol, l-isopulegol, and peppermint oil. A preferred cooling agent is l-menthol. The content of the cooling agent is preferably 0.1 to 3 mass% or 0.5 to 3 mass% based on the total mass of the paste layer. The content of l-menthol is preferably 0.1 to 0.5 mass%, and more preferably 0.2 to 0.4 mass%, based on the total mass of the paste layer. If the content of l-menthol is 0.1 mass% or more, the user of the poultice can be given a sufficient cooling sensation. If the content of l-menthol is 0.5 mass% or less, the storage stability of ketoprofen is more excellent.

[0044] Examples of stabilizers include oxybenzone, dibutylhydroxytoluene (BHT), sodium edetate, UV absorbers (for example, dibenzoylmethane derivatives), etc. The content of the stabilizer is preferably 0.5 to 3% by mass based on the mass of the paste layer.

[0045] The mass of the paste layer is 214 to 1000 g / m 2 and 400 to 1000 g / m 2 and 400 to 650 g / m 2 Preferably, the thickness is 400 to 650 g / m 2When the mass of the paste layer is within the above range, the overall thickness of the poultice can be reduced, the poultice can easily conform to the skin, and the difference in level with the peripheral edge when applied is reduced, so that the poultice tends not to peel off.

[0046] The pH of the paste layer is preferably 4 to 8, more preferably 4.5 to 6. By setting the pH at 4 or higher, irritation to the skin is reduced, and by setting the pH at 8 or lower, the moldability and shape retention of the poultice can be improved. In particular, when the support is a woven fabric, particularly a knitted fabric, bleeding may occur when the paste layer is formed, but bleeding tends to be suppressed when the pH is 5 to 6.5. The pH can be measured, for example, according to the pH measurement method of the general test method of the Japanese Pharmacopoeia, using a glass composite electrode and diluting the sample 20 times with purified water.

[0047] The poultice may be provided with a release liner. The release liner is laminated on the surface of the paste layer opposite the support. The provision of the release liner tends to suppress a decrease in the water content of the paste layer during storage, and to reduce adhesion of dirt and the like to the paste layer.

[0048] The material of the release liner is not particularly limited, and a liner made of a material generally known to those skilled in the art can be used. When a woven fabric, a nonwoven fabric, a knitted fabric, or a resin film is used as the support, the material of the release liner can be, for example, polyethylene, polypropylene, polybutylene, polyethylene terephthalate, rayon, or polyurethane, and one type can be used alone or two or more types can be used in combination. The material of the release liner is preferably polypropylene film.

[0049] The poultice may be stored inside a pouch. By storing the poultice inside a pouch, a decrease in the water content of the paste layer can be suppressed, and adhesion of dirt and the like to the paste layer can be reduced.

[0050] The poultice can be produced, for example, by mixing ketoprofen, propylene glycol, and water, adding the optional ingredients described above to obtain a paste liquid, spreading this paste liquid evenly on a release liner, and laminating a support thereon.

[0051] The present invention also has an aspect of a method for stabilizing ketoprofen in a poultice comprising a paste layer containing ketoprofen or a pharma- ceutically acceptable salt thereof on a support, the paste layer containing propylene glycol in an amount by mass three times or less the mass of ketoprofen. EXAMPLES

[0052] The present invention will be described in detail below using examples and test examples, but the present invention is not limited to these examples. Furthermore, the numbers in Tables 1, 3, and 5 represent mass % unless otherwise specified.

[0053] Examples 1 to 4 and Comparative Examples 1 to 6 (1) Manufacturing of poultices A plaster liquid was obtained by mixing the components shown in Table 1 for a certain period of time. The obtained plaster liquid was evenly spread on a release liner so that the plaster mass per cataplasm (140 mm x 100 mm) was 6 g, and then a knitted fabric (backing material) was immediately laminated thereon to produce a cataplasm. [Table 1]

[0054] (2) Evaluation of storage stability The obtained cataplasm was stored at 60° C. for 2 weeks. After storage, the cataplasm was applied to a skin with an area of ​​35 cm 2 After cutting into pieces (5 cm x 7 cm), the release liner was removed and the paste layer was extracted with 30 mL of methanol to obtain a sample solution. The content of ketoprofen and the total content of ketoprofen esters (glycerin, propylene glycol, menthol, or ethylhexyl esters of ketoprofen) in the sample solution were calculated based on the peak areas by high performance liquid chromatography (HPLC).

[0055] The results are shown in Table 2. The total amount of ketoprofen esters was calculated as a relative value (mol%) when the amount of ketoprofen at the time of production of the cataplasm was taken as 100. The amount of ketoprofen in each Example was 95% or more based on the content of ketoprofen at the time of production of the cataplasm. Meanwhile, the amount of ketoprofen esters was 2.2% or more in Comparative Examples 1 to 6, but less than 2.1% in Examples 1 to 4. The total amount of esters was even lower in the cataplasms of Examples 3 and 4, which contained hexyl laurate. [Table 2]

[0056] Examples 5 to 10 and Comparative Examples 7 to 13 (1) Manufacturing of poultices A plaster liquid was obtained by mixing the components shown in Table 3 for a certain period of time. The obtained plaster liquid was evenly spread on a release liner so that the plaster mass per cataplasm (140 mm x 100 mm) was 6 g, and then a knitted fabric (backing material) was immediately laminated thereon to produce a cataplasm. [Table 3]

[0057] (2) Evaluation of storage stability According to the above-mentioned method, the content of ketoprofen and the total content of ketoprofen esters in the sample solution were calculated based on the peak area by high performance liquid chromatography (HPLC).

[0058] The results are shown in Table 4. The amount of ketoprofen in each Example was 95% or more based on the ketoprofen content at the time of manufacturing the poultice. Meanwhile, the amount of ketoprofen ester was 2.29% or more in Comparative Examples 7 to 13, but less than 2.1% in Examples 5 to 10. [Table 4]

[0059] Example 11 and Comparative Examples 14 to 15 (1) Manufacturing of poultices A plaster liquid was obtained by mixing the components shown in Table 5 for a certain period of time. The obtained plaster liquid was evenly spread on a release liner so that the plaster mass per cataplasm (140 mm x 100 mm) was 6 g, and then a knitted fabric (backing material) was immediately laminated thereon to produce a cataplasm. [Table 5]

[0060] (2) Evaluation of storage stability According to the above-mentioned method, the content of ketoprofen and the total content of ketoprofen esters in the sample solution were calculated based on the peak area by high performance liquid chromatography (HPLC).

[0061] The results are shown in Table 6. In Comparative Examples 14 and 15, the total amount of ketoprofen esters was 2.5% or more, and in Example 11, it was 2% or less. [Table 6]

Claims

1. A poultice comprising a paste layer on a support, the paste layer contains ketoprofen or a pharma- ceutically acceptable salt thereof, propylene glycol, 1-menthol, water, at least one of poly(methyl acrylate / 2-ethylhexyl acrylate) and poly(methacrylic acid / n-butyl acrylate), glycerin, and a fatty acid alkyl ester; the mass of propylene glycol in the paste layer is 3 times or less the mass of ketoprofen; the content of 1-menthol is 0.1 to 0.5% by mass based on the total mass of the paste layer; the content of glycerin is 15 to 40% by mass based on the total mass of the paste layer, the content of the fatty acid alkyl ester is 0.5 to 15% by mass based on the total mass of the paste layer; The poultice has a propylene glycol content of 1.5 to 6.5% by mass based on the total mass of the paste layer.

2. A method for stabilizing ketoprofen in a poultice having a paste layer on a support, comprising: mixing ketoprofen or a pharma- ceutically acceptable salt thereof, 1-menthol, water, at least one of poly(methyl acrylate / 2-ethylhexyl acrylate) and poly(methacrylic acid / n-butyl acrylate), propylene glycol in an amount three times or less by mass of ketoprofen, glycerin, and a fatty acid alkyl ester to obtain a plaster liquid; spreading the paste liquid on a release liner to form a paste layer; the content of 1-menthol is 0.1 to 0.5% by mass based on the total mass of the paste layer; the amount of glycerin is 15 to 40% by mass based on the total mass of the paste layer; the amount of the fatty acid alkyl ester is 0.5 to 15% by mass based on the total mass of the paste layer; A method for stabilizing ketoprofen, wherein the amount of propylene glycol is 1.5 to 6.5% by mass based on the total mass of the paste layer.

Citation Information

Patent Citations

  • Gel preparation for transcutaneous absorption

    JP1991223212A

  • Gelatinous material and therapeutic gel pharmaceutical using the same

    JP1993065224A

  • Anti-inflammatory analgesic agent for external use

    JP1994199701A

  • Poultice

    JP1998095728A

  • External preparation composition

    JP2004067562A